The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies
Open accessAbstract
The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer treatment. Despite the excellent disease control with initial EGFR TKI therapy, acquired resistance is ubiquitous and remains a key challenge. Investigations into the mechanisms which foster resistance to EGFR TKIs has led to the discovery of novel biomarkers and drug targets, and in turn has enabled the development of third-generation TKIs and proposals for rational therapeutic combinations. The threonine-to-methionine substitution mutation at position 790 (T790M) is clinically validated to engender refractoriness to first- and second-generation TKIs, and is a standard-of-care predictive biomarker used in therapeutic stratification. Clinical use of liquid biopsy approaches for assessment of T790M mutations continues to increase, with growing advocacy for serial monitoring of tumor evolution. For patients who are T790M-negative, cytotoxic chemotherapy or protracted EGFR TKI treatment are acceptable treatment standards after disease progression, although combinations of targeted therapies and checkpoint blockade immunotherapy may offer promising alternatives in the future. Among T790M-positive patients, the third-generation EGFR TKI, osimertinib, has shown superiority over both platinum-doublet chemotherapy and 1st generation EGFR TKI in randomized clinical trials, and exhibits enhanced in vitro selectivity for mutant EGFR receptors and pharmacokinetics compared to earlier-generation TKIs. This article appraises the key literature on the contemporary management of non-small cell lung cancer patients with acquired resistance to EGFR TKIs, and envisions future directions in translational and clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70604-1 · Cited by 1,978
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Self-citationYang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Ballard, P., Yates, J. W. T., Yang, Z., Kim, D.-W., Yang, J. C.-H., Cantarini, M., Pickup, K., Jordan, A., Hickey, M., Grist, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0399 · Cited by 718
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Aisner, D. L., Gaspar, L. E., Kavanagh, B. D., Doebele, R. C., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745948 · Cited by 684
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 648
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647
Vuoriluoto, K., Haugen, H., Kiviluoto, S., Mpindi, J.-P., Nevo, J., Gjerdrum, C., Tiron, C., Lorens, J. B., & Ivaska, J. (2011) · Oncogene · doi:10.1038/onc.2010.509 · Cited by 647
Goss, G., Tsai, C.-M., Shepherd, F. A., Bazhenova, L., Lee, J. S., Chang, G.-C., Crino, L., Satouchi, M., Chu, Q., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 645
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J. C.-H., Mok, T., Lee, K. H., Lu, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw611 · Cited by 524
Guix, M., Faber, A. C., Wang, S. E., Olivares, M. G., Song, Y., Qu, S., Rinehart, C., Seidel, B., Yee, D., Arteaga, C. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34588 · Cited by 521
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504
Lee, C. K., Brown, C., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C.-M., Tan, E. H., Ho, J. C.-M., Chu, D. T., Zaatar, A., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt072 · Cited by 501
Thress, K. S., Brant, R., Carr, T. H., Dearden, S., Jenkins, S., Brown, H., Hammett, T., Cantarini, M., & Barrett, J. C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.10.004 · Cited by 493
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0399 · Cited by 458
Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00121-7 · Cited by 413
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Oxnard, G. R., Arcila, M. E., Chmielecki, J., Ladanyi, M., Miller, V. A., & Pao, W. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2571 · Cited by 349
Sundaresan, T. K., Sequist, L. V., Heymach, J. V., Riely, G. J., Jänne, P. A., Koch, W. H., Sullivan, J. P., Fox, D. B., Maher, R., Muzikansky, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1031 · Cited by 347
Yu, H. A., Sima, C. S., Huang, J., Solomon, S. B., Rimner, A., Paik, P., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827e1f83 · Cited by 341
Giving AXL the axe: targeting AXL in human malignancy
Gay, C. M., Balaji, K., & Byers, L. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.428 · Cited by 334
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
Planchard, D., Loriot, Y., André, F., Gobert, A., Auger, N., Lacroix, L., & Soria, J. C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv319 · Cited by 311
Eberlein, C. A., Stetson, D., Markovets, A. A., Al-Kadhimi, K. J., Lai, Z., Fisher, P. R., Meador, C. B., Spitzler, P., Ichihara, E., Ross, S. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3167 · Cited by 301
Jenkins, S., Yang, J. C.-H., Ramalingam, S. S., Yu, K., Patel, S., Weston, S., Hodge, R., Cantarini, M., Jänne, P. A., Mitsudomi, T., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.003 · Cited by 269
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
Ortiz-Cuaran, S., Scheffler, M., Plenker, D., Dahmen, L., Scheel, A. H., Fernandez-Cuesta, L., Meder, L., Lovly, C. M., Persigehl, T., Merkelbach-Bruse, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1915 · Cited by 259
Yu, H. A., Tian, S. K., Drilon, A. E., Borsu, L., Riely, G. J., Arcila, M. E., & Ladanyi, M. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1066 · Cited by 240
Ahn, M.-J., Yang, J., Yu, H., Saka, H., Ramalingam, S., Goto, K., Kim, S.-W., Yang, L., Walding, A., & Oxnard, G. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30246-5 · Cited by 234
Park, K., Yu, C.-J., Kim, S.-W., Lin, M.-C., Sriuranpong, V., Tsai, C.-M., Lee, J.-S., Kang, J.-H., Chan, K. C. A., Perez-Moreno, P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4921 · Cited by 229
Mechanisms of Acquired Resistance to AZD9291
Kim, T. M., Song, A., Kim, D.-W., Kim, S., Ahn, Y.-O., Keam, B., Jeon, Y. K., Lee, S.-H., Chung, D. H., & Heo, D. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000688 · Cited by 222
Wang, Z., Yang, J.-J., Huang, J., Ye, J.-Y., Zhang, X.-C., Tu, H.-Y., Han-Zhang, H., & Wu, Y.-L. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.017 · Cited by 221
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Ho, C.-C., Liao, W.-Y., Lin, C.-A., Shih, J.-Y., Yu, C.-J., & Chih-Hsin Yang, J. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2231 · Cited by 219
Chouaid, C., Dujon, C., Do, P., Monnet, I., Madroszyk, A., Le Caer, H., Auliac, J. B., Berard, H., Thomas, P., Lena, H., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.016 · Cited by 187
Cortot, A. B., Repellin, C. E., Shimamura, T., Capelletti, M., Zejnullahu, K., Ercan, D., Christensen, J. G., Wong, K.-K., Gray, N. S., & Jänne, P. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2066 · Cited by 185
Karlovich, C., Goldman, J. W., Sun, J.-M., Mann, E., Sequist, L. V., Konopa, K., Wen, W., Angenendt, P., Horn, L., Spigel, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1260 · Cited by 179
Shi, P., Oh, Y.-T., Zhang, G., Yao, W., Yue, P., Li, Y., Kanteti, R., Riehm, J., Salgia, R., Owonikoko, T. K., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.021 · Cited by 177
L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC
Bersanelli, M., Minari, R., Bordi, P., Gnetti, L., Bozzetti, C., Squadrilli, A., Lagrasta, C. A. M., Bottarelli, L., Osipova, G., Capelletto, E., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.019 · Cited by 167
Yang, J.-J., Chen, H.-J., Yan, H.-H., Zhang, X.-C., Zhou, Q., Su, J., Wang, Z., Xu, C.-R., Huang, Y.-S., Wang, B.-C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.016 · Cited by 164
Soo, R. A., Lim, S. M., Syn, N. L. X., Teng, R. S. Y., Soong, R., Mok, T. S. K., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.009 · Cited by 158
Self-citationOu, S. I., Cui, J., Schrock, A. B., Goldberg, M. E., Zhu, V. W., Albacker, L. A., Stephens, P. J., Miller, V. A., & Ali, S. M. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.003 · Cited by 154
Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150
Ou, S.-H. I., Agarwal, N., & Ali, S. M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.015 · Cited by 149
Rizvi, N. A., Chow, L. Q. M., Borghaei, H., Shen, Y., Harbison, C. T., Alaparthy, S., Chen, A. C., & Gettinger, S. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8022 · Cited by 119
Song, H., Jung, K. S., Yoo, K. H., Cho, J., Lee, J. Y., Lim, S. H., Kim, H. S., Sun, J., Lee, S., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.093 · Cited by 118
Self-citationGibbons, D. L., Chow, L. Q. M., Kim, D.-W., Kim, S., Yeh, T. C., Song, X., Jiang, H., Taylor, R., Karakunnel, J. J., & Creelan, B. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30171-x · Cited by 112
Yoon, H. J., Lee, H. Y., Lee, K. S., Choi, Y., Ahn, M., Park, K., Ahn, J. S., Sun, J., Kim, J., Kim, T. S., et al. (2012) · Radiology · doi:10.1148/radiol.12112613 · Cited by 107
Tan, C.-S., Cho, B.-C., & Soo, R. A. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.003 · Cited by 105
Self-citationResistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
Ham, J. S., Kim, S., Kim, H. K., Byeon, S., Sun, J., Lee, S.-H., Ahn, J. S., Park, K., Choi, Y., Han, J., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.013 · Cited by 89
Chen, K., Zhou, F., Shen, W., Jiang, T., Wu, X., Tong, X., Shao, Y. W., Qin, S., & Zhou, C. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.024 · Cited by 89
Gandara, D. R., Li, T., Lara, P. N., Kelly, K. L., Riess, J. W., Redman, M. W., & Mack, P. C. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.10.001 · Cited by 85
Popat, S., Wotherspoon, A. C., Nutting, C. M., de Castro, D. G., Nicholson, A. G., & O'Brien, M. E. R. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.019 · Cited by 83
Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma
Capaccione, K. M., Hong, X., Morgan, K. M., Liu, W., Bishop, M. J., Liu, L., Markert, E. K., Deen, M. F., Minerowicz, C., Bertino, J. R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1970 · Cited by 82
Martínez‐Martí, A., Felip, E., Matito, J., Mereu, E., Navarro, A., Cedrés, S., Pardo, N., de Castro, A. M. M., Remón, J., Miquel, J. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx396 · Cited by 77
Aw, D. C., Tan, E. H., Chin, T. M., Lim, H. L., Lee, H. Y., & Soo, R. A. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12687 · Cited by 73
Self-citationTransformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report
Li, L., Wang, H., Li, C., Wang, Z., Zhang, P., & Xu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.14506 · Cited by 63
Mok, T. S. K., Ahn, M., Han, J., Kang, J. H., Katakami, N., Kim, H. R., Hodge, R. A., Ghiorghiu, D. C., Cantarini, M., Wu, Y.-L. L. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9005 · Cited by 63
Tan, C., Cho, B. C., & Soo, R. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.012 · Cited by 45
Self-citationStructural pharmacological studies on EGFR T790M/C797S
Kong, L., Ma, R., Yao, M.-Y., Yan, X.-E., Zhu, S., Zhao, P., & Yun, C. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.138 · Cited by 45
Wu, Y.-L. L. C., Yang, J. C., Kim, D., Su, W., Ahn, M., Lee, K. H., Vansteenkiste, J., Zhang, L., Felip, E., Peng, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8017 · Cited by 44
Ma, B. B. Y., Rudin, C. M., Cervantes, A. M. R., Dowlati, A., Costa, D. B., Schmid, P., Heist, R. S., Villaflor, V. M., Sarkar, I., Huseni, M. A., et al. (2016) · Annals of Oncology · doi:10.1016/s0923-7534(21)00599-8 · Cited by 41
Ma, B. B. Y., Rudin, C. M., Cervantes, A. M. R., Dowlati, A., Costa, D., Schmid, P., Heist, R., Villaflor, V. M., Sarkar, I., Huseni, M. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw594.005 · Cited by 41
Ni, Y., Bi, J., Ye, X., Fan, W., Yu, G., Yang, X., Huang, G., Li, W., Wang, J., Han, X., et al. (2016) · Medicine · doi:10.1097/md.0000000000003998 · Cited by 37
Tan, D. S.-W., Lim, K. H., Tai, W. M. D., Ahmad, A., Pan, S., Ng, Q. S., Ang, M., Gogna, A., Ng, Y. L., Tan, B. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8107 · Cited by 30
Analysis of intratumor heterogeneity unravels lung cancer evolution
de Bruin, E. C., McGranahan, N., & Swanton, C. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.985549 · Cited by 29
Menon, R., Müller, J. N., Schneider, P. M., Lakis, S., Thress, K. S., Wolf, J., Heukamp, L. C., Heuckmann, J. M., & Griesinger, F. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.005 · Cited by 28
Goss, G. D., Tsai, C., Shepherd, F. A., Ahn, M., Bazhenova, L. A., Crinò, L., de Marinis, F., Felip, E., Morabito, A., Hodge, R. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.514 · Cited by 27
Wu, Y.-L. L. C., Jenkins, S. C., Ramalingam, S. S., Han, J., Delmonte, A., Hsia, T., Laskin, J. J., Kim, S., He, Y., Patel, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.436 · Cited by 24
Ou, Q., Wu, X., Bao, H., Tong, X., Wang, X., Zhang, X., Chang, Z., Mao, Y., Shao, Y. W., & Zhou, C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2572 · Cited by 18
Oxnard, G. R., Hu, Y., Mileham, K. F., Tracy, P. D., Feeney, N. B., Sholl, L. M., Paweletz, C. P., Thress, K. S., & Janne, P. A. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.376 · Cited by 16
Soria, J., Kim, S. W., Wu, Y.-L. L. C., Nakagawa, K., Yang, J., Ahn, M.-J., Wang, J., Yang, J. C., Lü, Y., Atagi, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw383.01 · Cited by 14
Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?
Franceschi, E., de Biase, D., Paccapelo, A., Mura, A., Tosoni, A., Bartolini, S., Tallini, G., Pession, A., Danieli, D., Rossi, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2017 · Cited by 11
Piotrowska, Z., Nagy, R. J., Fairclough, S. R., Lanman, R. B., Marcoux, N., Gettinger, S. N., Owonikoko, T. K., Ramalingam, S., & Sequist, L. V. D. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.375 · Cited by 11
Cited by
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Wu, Y.-L., Cheng, Y., Zhou, J., Lu, S., Zhang, Y., Zhao, J., Kim, D.-W., Soo, R. A., Kim, S.-W., Pan, H., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30154-5 · Cited by 258
Self-citation
Metadata
- Authors
- Lim, S. M., Syn, N. L., Cho, B. C., & Soo, R. A.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 65
- Pages
- 1-10
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2794026637
- Cited by
- 288
- References
- 101
- FWCI
- 19.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.